CN Patent

CN113993860B — 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2023-08-01 · 3y expired

What this patent protects

一类KRAS G12C突变蛋白抑制剂，具体公开了式(II)所示化合物及其异构体、药学上可接受的盐。

USPTO Abstract

一类KRAS G12C突变蛋白抑制剂，具体公开了式(II)所示化合物及其异构体、药学上可接受的盐。

Drugs covered by this patent

Patent Metadata

Patent number
CN113993860B
Jurisdiction
CN
Classification
—
Expires
2023-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.